To explore BLCA-4 expression and perform short tandem repeat (STR) genotyping using blood and urine samples from smokers and non-smokers with bladder cancer, alongside healthy controls, with a focus on comparing the results between these groups.
Key Findings:
Mean BLCA-4 concentration was significantly elevated in both BC-S and BC+S groups compared to HPG (P < 0.01), indicating a potential biomarker for bladder cancer.
Low-grade urothelial tumors were detected in BC-S samples, while high-grade tumors were found in BC+S samples, highlighting the impact of smoking on tumor aggressiveness.
Changes were observed at four STR loci (CSF1PO, D21S11, D7S820, D2S1338), while five loci remained unchanged in LOH and MSI analysis, suggesting specific genetic alterations associated with smoking.
Interpretation:
Urine samples can be effectively used for diagnosing and predicting bladder cancer through STR genotyping, particularly in relation to smoking history, which may inform clinical decision-making.
Limitations:
The study's findings are based on a specific population and may not be generalizable to all demographics.
Further research is needed to validate the findings across diverse populations and to explore the clinical implications of the identified biomarkers.
Conclusion:
The study supports the use of urine samples for comprehensive analysis of bladder cancer biomarkers and genetic alterations related to smoking, emphasizing the importance of smoking history in bladder cancer diagnostics.
